The use of pharmacological inhibitors has suggested a key role for purinergic receptors in synaptic plasticity and in many neuronal diseases.
| INTRODUC TI ON
The use of pharmacological inhibitors has suggested a key role for purinergic receptors in synaptic plasticity and in many neuronal diseases. 1 Until recently, the specific receptors involved were not well understood; however, such studies relied exclusively on the use of pharmacological agents that cannot truly discriminate between purinergic receptors. 2 Purinergic receptor knockouts (rKO) have provided a way to overcome these pharmacological limitations. 3, 4 Such knockouts have been vital in clarifying the role of ATP receptors in the pain mechanisms of sensory neurones 5 and for establishing which types of purinergic receptors are modulating neuropeptide release. 4 ,6
| ATP
The importance of ATP as a neurotransmitter is demonstrated by its extensive involvement in multiple processes throughout the nervous system, including modulation of long-term potentiation and depression, pain transduction, bladder control, modulation of vascular tone and control of the gastrointestinal system. 7-9 ATP may affect plasticity differentially, depending upon which type of purinergic receptor it activates and whether that receptor is located pre-or postsynaptically. [8] [9] [10] [11] [12] Thus, the ATP receptor subtype and its localisation at central nervous system (CNS) synapses is critical but, for the most part, still unknown.
Many different types of purinergic receptors are present in the hypothalamicneurohypophysial system (HNS), which synthesises and releases vasopressin and oxytocin. The specific location of purinergic receptor subtypes has important functional repercussions for neuronal activity and synaptic output. Yet, until the advent of receptor knockouts, this had been hindered by the low selectivity of the available pharmacological tools. The HNS offers an excellent opportunity to differentiate the functional properties of these purinergic receptors in cell bodies vs terminals of the same physiological system. P2X2, P2X3, P2X4 and P2X7 receptors are present in vasopressin terminals, whereas oxytocin terminals exclusively express the P2X7 subtype. The latter is not functional in the cell bodies of the HNS. These purinergic receptor subtypes are permeable to sodium vs calcium in varying amounts and this could play an important role in the release of vasopressin vs oxytocin during bursting activity. Endogenous ATP and its metabolite, adenosine, have autocrine and paracrine modulatory effects on the release of these neuropeptides during physiological stimulation. Finally, we hypothesise that, during such action potential bursts, ATP potentiates the release of vasopressin but not of oxytocin, and that adenosine, via A1
receptors, inhibits the release of both neuropeptides.
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Extracellular ATP communicates physiological signals via the activation of P2X ligand-gated cation channels (ionotropic) and P2Y Gprotein-coupled (metabotropic) receptors. Of the seven P2X receptor subunits (P2X1 to P2X7), a great deal of evidence supports a major role for the P2X2 and P2X3 subunits in mediating the primary effects of ATP on sensory neurones. 7, 13 The P2Y receptor has important functions in glia of the neurohypophysis, 14 as well as in modulation of microglial cell activation. 15 ATP increases intracellular calcium in supraoptic neurones by activation of both P2X and P2Y purinergic receptors. 16 However, the relative contribution of these receptor subtypes to different functions of ATP is still poorly understood. 3 
| ADENOS INE
Adenosine, which is a product of ATP hydrolysis, is produced by ecto-ATPases 17 localised to the outer surface of plasma membranes ( Figure 1 ). This purine interacts with a family of four (A1, A2a, A2b and A3) adenosine receptors. 18, 19 The A1 receptor, in particular, is highly and widely expressed in the brain. 20 Adenosinemediated effects that occur via the A1 receptor include depression of neurotransmission, sleep induction, antinociception and ethanolinduced motor incoordination. 19, 21 Adenosine also inhibits voltagedependent Ca 2+ currents in rat dissociated supraoptic neurones via A1 receptors. 22 Adenosine receptors are major targets of caffeine, which is the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets for many conditions, including cerebral and cardiac ischaemias, sleep disorders, immune and inflammatory disorders, and cancer. 1 Activation of adenosine A2a receptors alters postsynaptic currents and depolarises neurones of the supraoptic nucleus. 23 The A2b
receptor also mediates adenosine inhibition of taurine efflux from pituicytes in neurohypophysis. 24 The A3-receptor subtype, however, has no relevant effect on hypothalamic activity. 24 
| HYP OTHAL AMIC-NEUROHYP OPHYS IAL SYS TEM
In the hypothalamic-neurohypophysial system (HNS), two neuropeptides, vasopressin (AVP) and oxytocin (OT), are synthesised in magnocellular neurones located in the hypothalamus and released at peripheral sites in the neurohypophysis. 25 Both hormones may also be central neurotransmitters and have been implicated in sexual behaviour, 26 stress, learning and memory processes. 27 Purinergic receptors are present 28, 29 throughout the HNS. 30 Local regulation of vasopressin and oxytocin secretion by extracellular ATP has been demonstrated in the isolated posterior lobe of the rat neurohypophysis. 31, 32 In the intact HNS, however, purinergic and adrenergic agonists appear to synergise in stimulating vasopressin and oxytocin release. 4 In agreement with the electrophysiological results, P2X2 receptors specifically regulate AVP release, 37 whereas OT release appears to be regulated by P2X7
receptors. 36 By contrast, activation of adenosine receptors inhibits the release of both neuropeptides. 38 We have also examined P2X7R localisation 36 using a stereospecific ecto-P2X7 antibody. Although the SON and PVN contain its mRNA 29 and show P2X7R immunoreactivity (IR), the receptor is absent from membranes of magnocellular neurones. By contrast, AVP-and OT-terminals demonstrate P2X7R-IR, suggesting that this receptor subtype is only targeted to the plasma membrane of secretory terminals ( Figure 1) . 28 Taken together, these pharmacological and immunohistochemical results are consistent with the presence of a functional P2X7R in both types of HNS terminals. We consider that this helps clear up a major P2X7R controversy with respect to whether P2X7Rs are actually functional in neurones. Thus, our data establish that these receptors are only functional at terminals and not at somata of neurones. 28, 35, 36 To our knowledge, this is the first direct evidence of a P2X7R function in neurones.
| RECEP TOR I ON S ELEC TIVIT Y
The P2X receptor subtypes are known to be cation selective. 13 We have recently shown that both sodium (Na . Thus, these receptors might be localised not only to different terminal types, but also to different functional areas of the same terminals (Figure 1 ). P2X2 and/or P2X3 receptors could be colocalised with release sites and thus Ca 2+ entry through them can directly cause release. By contrast, P2X7 receptors could be localised away from release sites, so that only Na + entry through them can cause release. 39 Because extracellular Ca 2+ is depleted during bursting stimulation of these NH terminals, 40 these differences could play an important role during such physiological activity. 41 
| ENDOG ENOUS PURINE S
ATP is concentrated in the secretory granules of the NH 42 and is coreleased with the neuropeptides. 6, 31, 32, 37 Although there is possible regulation by pannexin channels of ATP-induced currents in vasopressin neurones from the rat supraoptic nucleus, there appears to be no release of ATP via connexin channels. 43 Endogenous ATP and its metabolite adenosine have autocrine and paracrine modulatory effects on the release of AVP vs OT 41 during physiological bursting patterns of stimulation. 44 Activitydependent feedback modulation of spike patterning of supraoptic nucleus neurones by endogenous adenosine has been shown to occur via A1R. 40 This means that similar or even greater levels of endogenous adenosine should be achieved in NH during a burst stimulation. 37 Our group, 35 as well as others, 14, 15 have shown that ATP is released in sufficient quantities to affect purinergic receptors in the HNS and subsequent release of the peptides. Finally, using loose-patch clamp on the intact neurohypophysis, the A1 antagonist 8-cyclopentyltheophylline (CPT) increased voltage-dependent currents in wild-type but not in adenosine receptor A1KO mice. In agreement, pretreatment with CPT potentiated electrically-stimulated AVP and OT release from wild-type mice by approximately 20% but had no effect on A1KO mice. 6 
| MODEL
As a result of these data, we hypothesise 30 
| CON CLUS IONS
The HNS provides an excellent example of a physiological system where the specific expression and localisation of purinergic receptor subtypes modulates neuronal activity and has profound implications on how synaptic output is regulated. The HNS shows differences in functional purinergic receptors not only between cell bodies and their terminals, 28 but also between and within terminal types. Furthermore, it has allowed resolution of the functional P2X7 receptor controversy in neurones. 36 The use of specific knockouts for purinergic receptors is an important tool that has clarified their functions at specific cellular compartments of these CNS neurones.
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